Biopharma | January 01, 2026
Savara resubmits FDA application for potential treatment in rare lung disease patients
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
This marks the first partnership between Pfizer and Cipla in India
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
A triple-action Formula for comprehensive respiratory relief
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
EBITDA before special items decreases to €4.08 billion (7.4%)
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Subscribe To Our Newsletter & Stay Updated
